Penumbra Inc.
Penumbra, Inc. Reports Second Quarter 2024 Financial Results
Summary
Penumbra, Inc. reported financial results for the second quarter of 2024, showing a revenue of $299.4 million, an increase of 14.5% compared to Q2 2023. The company reported a loss from operations of $81.0 million, which includes $110.3 million of one-time non-cash impairment and inventory write-down charges. Adjusted EBITDA was $46.3 million. The company also updated its full-year 2024 financial outlook, reducing the midpoint of its revenue guidance by $60 million due to various factors including a more challenging economic backdrop in China and delays in Europe.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement